

# **U.S. Pharmaceutical Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Type, By Product, By Services, By Workflow, By Therapeutic Area, By End Use, And Segment Forecasts, 2025 - 2033**

<https://marketpublishers.com/r/U366C97C2C9FEN.html>

Date: September 2025

Pages: 120

Price: US\$ 5,950.00 (Single User License)

ID: U366C97C2C9FEN

## **Abstracts**

### **U.S. Pharmaceutical Contract Development & Manufacturing Organization Market Summary**

The U.S. pharmaceutical contract development and manufacturing organization market size was estimated at USD 36.5 billion in 2024 and is projected to reach USD 65.3 billion by 2033, growing at a CAGR of 6.74% from 2025 to 2033. The U.S. pharmaceutical contract development & manufacturing organization (CDMO) is advancing, driven by the growth of biologics, biosimilars, and advanced therapies, rising demand for outsourcing in drug development, and increasing clinical trial activity and pipeline expansion.

The U.S. market is witnessing significant growth in biologics, biosimilars, and advanced cell and gene therapies, fueling demand for specialized CDMO services. Developing and manufacturing these therapies requires advanced capabilities like single-use bioprocessing systems, viral vector production, and personalized medicine expertise, which many pharma companies lack in-house.

CDMOs provide infrastructure, regulatory knowledge, and innovation platforms to accelerate development while meeting FDA standards. With rising approvals of biologics and biosimilars in the U.S., CDMOs are becoming indispensable partners in scaling production, ensuring supply chain resilience, and enabling faster time-to-market for complex, high-value therapeutics.

## U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. pharmaceutical CDMO market report based on type, product, service, workflow, therapeutic area, and end use:

### Type Outlook (Revenue, USD Million, 2021 - 2033)

#### Small Molecule

- Branded

- Generic

#### Large Molecule

- Biologics

- Biosimilar

### Product Outlook (Revenue, USD Million, 2021 - 2033)

#### API

- Traditional Active Pharmaceutical Ingredient (Traditional API)

- Highly Potent Active Pharmaceutical Ingredient (HP-API)

- Biologics

- Others

#### Drug Product

- Oral solid dose

Semi-solid dose

Liquid dose

Others

Service Outlook (Revenue, USD Million, 2021 - 2033)

Contract Development

Pre-formulation & Formulation Development Services

Process Development & Optimization

Analytical Testing & Method Validation

Scale-up & Tech Transfer

Contract Manufacturing

API Manufacturing

Finished Drug Products Manufacturing

Packaging and Labelling

Regulatory Affairs

Others

Workflow Outlook (Revenue, USD Million, 2021 - 2033)

Clinical

Commercial

Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)

Oncology

Infectious Diseases

Neurological Disorders

Cardiovascular Disease

Metabolic Disorders

Autoimmune Diseases

Respiratory Diseases

Ophthalmology

Gastrointestinal Disorders

Orthopedic Diseases

Dental Diseases

Others

End Use Outlook (Revenue, USD Million, 2021 - 2033)

Small Pharmaceutical Companies

Medium Pharmaceutical Companies

Large Pharmaceutical Companies

**This report can be delivered to the clients within 2 Business Days**

## Contents

### **CHAPTER 1. RESEARCH METHODOLOGY AND SCOPE**

- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
  - 1.2.1. Type
  - 1.2.2. Product
  - 1.2.3. Services
  - 1.2.4. Workflow
  - 1.2.5. Therapeutic Area
  - 1.2.6. End Use
- 1.3. Research Methodology
- 1.4. Information Procurement
  - 1.4.1. Purchased Database
  - 1.4.2. GVR's Internal Database
  - 1.4.3. Secondary Sources
  - 1.4.4. Primary Research
- 1.5. Information Or Data Analysis
  - 1.5.1. Data Analysis Models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
  - 1.7.1. Commodity Flow Analysis
  - 1.7.2. Top-Down Analysis
  - 1.7.3. Botton-Up Approach
  - 1.7.4. Multivariate Analysis
- 1.8. List Of Secondary Sources
- 1.9. List Of Abbreviations
- 1.10. Objectives

### **CHAPTER 2. EXECUTIVE SUMMARY**

- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights

### **CHAPTER 3. U.S. PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET VARIABLES, TRENDS & SCOPE**

- 3.1. Market Lineage Outlook
  - 3.1.1. Parent Market Outlook
  - 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
  - 3.2.1. Market Driver Analysis
  - 3.2.2. Market Restraint Analysis
  - 3.2.3. Market Opportunity Analysis
- 3.3. R&D Spending Analysis
- 3.4. Industry Ecosystem Analysis
  - 3.4.1. Demand Analysis
  - 3.4.2. Supply Chain Analysis
- 3.5. Technology Landscape
- 3.6. Clinical Trial Volume Analysis, 2024
- 3.7. Pricing Analysis
- 3.8. Tariff and Trade Agreement Impact Analysis
- 3.9. Value Chain Analysis
  - 3.9.1. Supply Trends
  - 3.9.2. Demand Trends
- 3.10. Market Analysis Tools
  - 3.10.1. Porter's Five Forces Analysis
  - 3.10.2. PESTEL by SWOT Analysis

## **CHAPTER 4. U.S. PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET: TYPE ESTIMATES & TREND ANALYSIS**

- 4.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Type: Segment Dashboard
- 4.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Type: Movement Analysis
- 4.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Type, 2021 - 2033 (USD Million)
- 4.4. Small Molecule
  - 4.4.1. Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 4.4.2. Branded
    - 4.4.2.1. Branded Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  - 4.4.3. Generic
    - 4.4.3.1. Generic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Large Molecule

4.5.1. Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)

4.5.2. Biologics

4.5.2.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

4.5.3. Biosimilar

4.5.3.1. Biosimilar Market Estimates and Forecasts, 2021 - 2033 (USD Million)

## **CHAPTER 5. U.S. PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET: PRODUCT ESTIMATES & TREND ANALYSIS**

5.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Product: Segment Dashboard

5.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Product: Movement Analysis

5.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million)

5.4. API

5.4.1. API Market Estimates and Forecasts, 2021 - 2033 (USD Million)

5.4.2. Traditional Active Pharmaceutical Ingredient (Traditional API)

5.4.2.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

5.4.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)

5.4.3.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

5.4.4. Biologics

5.4.4.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

5.4.5. Others

5.4.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

5.5. Drug Product

5.5.1. Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)

5.5.2. Oral Solid Dose

5.5.2.1. Oral Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)

5.5.3. Semi-Solid Dose

5.5.3.1. Semi-Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)

5.5.4. Liquid Dose

5.5.4.1. Liquid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)

5.5.5. Others

5.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

## **CHAPTER 6. U.S. PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET: SERVICE ESTIMATES & TREND ANALYSIS**

6.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Service: Segment Dashboard

6.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Service: Movement Analysis

6.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)

6.4. Contract Development

6.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)

6.4.2. Pre-formulation & Formulation Development Services

6.4.2.1. Pre-formulation & Formulation Development Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

6.4.3. Process Development & Optimization

6.4.3.1. Process Development & Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)

6.4.4. Analytical Testing & Method Validation

6.4.4.1. Analytical Testing & Method Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)

6.4.5. Scale-up & Tech Transfer

6.4.5.1. Scale-up & Tech Transfer Market Estimates and Forecasts, 2021 - 2033 (USD Million)

6.5. Contract Manufacturing

6.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

6.5.2. API Manufacturing

6.5.2.1. API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

6.5.3. Finished Drug Products Manufacturing

6.5.3.1. Finished Drug Products Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

6.6. Packaging and Labelling

6.6.1. Packaging and Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)

6.7. Regulatory Affairs

6.7.1. Regulatory Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)

## 6.8. Others

6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

## **CHAPTER 7. U.S. PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET: WORKFLOW ESTIMATES & TREND ANALYSIS**

7.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Workflow: Segment Dashboard

7.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Workflow: Movement Analysis

7.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)

### 7.4. Clinical

7.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)

### 7.5. Commercial

7.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)

## **CHAPTER 8. U.S. PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET: THERAPEUTIC AREA ESTIMATES & TREND ANALYSIS**

8.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Therapeutic Area: Segment Dashboard

8.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By Therapeutic Area: Movement Analysis

8.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033 (USD Million)

### 8.4. Oncology

8.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)

### 8.5. Infectious Diseases

8.5.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)

### 8.6. Neurological Disorders

8.6.1. Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)

### 8.7. Cardiovascular Diseases

8.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)

### 8.8. Metabolic Disorders

- 8.8.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.9. Autoimmune Diseases
  - 8.9.1. Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.10. Respiratory Diseases
  - 8.10.1. Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.11. Ophthalmology
  - 8.11.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.12. Gastrointestinal Disorders
  - 8.12.1. Gastrointestinal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.13. Orthopedic Diseases
  - 8.13.1. Orthopedic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.14. Dental Diseases
  - 8.14.1. Dental Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.15. Others
  - 8.15.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

## **CHAPTER 9. U.S. PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET: END USE ESTIMATES & TREND ANALYSIS**

- 9.1. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By End Use: Segment Dashboard
- 9.2. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market, By End Use: Movement Analysis
- 9.3. U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
- 9.4. Small Pharmaceutical Companies
  - 9.4.1. Small Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5. Medium Pharmaceutical Companies
  - 9.5.1. Medium Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6. Large Pharmaceutical Companies
  - 9.6.1. Large Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)

## CHAPTER 10. COMPETITIVE LANDSCAPE

### 10.1. Key Participant Categorization

#### 10.1.1. Market Leaders

#### 10.1.2. Emerging Players

### 10.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)

### 10.3. Company Profiles

#### 10.3.1. Thermo Fisher Scientific, Inc

##### 10.3.1.1. Company Overview

##### 10.3.1.2. Financial Performance

##### 10.3.1.3. Service Benchmarking

##### 10.3.1.4. Strategic Initiatives

#### 10.3.2. Lonza

##### 10.3.2.1. Company Overview

##### 10.3.2.2. Financial Performance

##### 10.3.2.3. Service Benchmarking

##### 10.3.2.4. Strategic Initiatives

#### 10.3.3. Recipharm AB

##### 10.3.3.1. Company Overview

##### 10.3.3.2. Financial Performance

##### 10.3.3.3. Service Benchmarking

##### 10.3.3.4. Strategic Initiatives

#### 10.3.4. Catalent, Inc

##### 10.3.4.1. Company Overview

##### 10.3.4.2. Financial Performance

##### 10.3.4.3. Service Benchmarking

##### 10.3.4.4. Strategic Initiatives

#### 10.3.5. WuXi AppTec, Inc

##### 10.3.5.1. Company Overview

##### 10.3.5.2. Financial Performance

##### 10.3.5.3. Service Benchmarking

##### 10.3.5.4. Strategic Initiatives

#### 10.3.6. Samsung Biologics

##### 10.3.6.1. Company Overview

##### 10.3.6.2. Financial Performance

##### 10.3.6.3. Service Benchmarking

##### 10.3.6.4. Strategic Initiatives

#### 10.3.7. Piramal Pharma Solutions

- 10.3.7.1. Company Overview
- 10.3.7.2. Financial Performance
- 10.3.7.3. Service Benchmarking
- 10.3.7.4. Strategic Initiatives
- 10.3.8. Siegfried Holding AG
  - 10.3.8.1. Company Overview
  - 10.3.8.2. Financial Performance
  - 10.3.8.3. Service Benchmarking
  - 10.3.8.4. Strategic Initiatives
- 10.3.9. Corden Pharma International
  - 10.3.9.1. Company Overview
  - 10.3.9.2. Financial Performance
  - 10.3.9.3. Service Benchmarking
  - 10.3.9.4. Strategic Initiatives
- 10.3.10. Cambrex Corporation
  - 10.3.10.1. Company Overview
  - 10.3.10.2. Financial Performance
  - 10.3.10.3. Service Benchmarking
  - 10.3.10.4. Strategic Initiatives
- 10.3.11. Vetter Pharma
  - 10.3.11.1. Company Overview
  - 10.3.11.2. Financial Performance
  - 10.3.11.3. Service Benchmarking
  - 10.3.11.4. Strategic Initiatives
- 10.3.12. Delpharm
  - 10.3.12.1. Company Overview
  - 10.3.12.2. Financial Performance
  - 10.3.12.3. Service Benchmarking
  - 10.3.12.4. Strategic Initiatives
- 10.3.13. Jubilant Pharmova / HollisterStier
  - 10.3.13.1. Company Overview
  - 10.3.13.2. Financial Performance
  - 10.3.13.3. Service Benchmarking
  - 10.3.13.4. Strategic Initiatives
- 10.3.14. Eurofins CDMO
  - 10.3.14.1. Company Overview
  - 10.3.14.2. Financial Performance
  - 10.3.14.3. Service Benchmarking
  - 10.3.14.4. Strategic Initiatives

### 10.3.15. Almac Pharma Services

10.3.15.1. Company Overview

10.3.15.2. Financial Performance

10.3.15.3. Service Benchmarking

10.3.15.4. Strategic Initiatives

## List Of Tables

### LIST OF TABLES

Table 1 List of Secondary Sources

Table 2 List of Abbreviations

Table 3 U.S. Pharmaceutical Contract Development And Manufacturing Organization Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)

Table 4 U.S. Pharmaceutical Contract Development And Manufacturing Organization Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)

Table 5 U.S. Pharmaceutical Contract Development And Manufacturing Organization Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)

Table 6 U.S. Pharmaceutical Contract Development And Manufacturing Organization Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)

Table 7 U.S. Pharmaceutical Contract Development And Manufacturing Organization Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)

Table 8 U.S. Pharmaceutical Contract Development And Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

## List Of Figures

### LIST OF FIGURES

- Fig. 1 Market research process
- Fig. 2 Information procurement
- Fig. 3 Primary research pattern
- Fig. 4 Market research approaches
- Fig. 5 Market formulation & validation
- Fig. 6 Commodity flow analysis
- Fig. 7 Value-chain-based sizing & forecasting
- Fig. 8 QFD model sizing & forecasting
- Fig. 9 Bottom-up approach
- Fig. 10 Market snapshot
- Fig. 11 Segment snapshot 1
- Fig. 12 Segment snapshot 2
- Fig. 13 Competitive landscape snapshot
- Fig. 14 Parent market outlook, 2024 (USD Billion)
- Fig. 15 Ancillary market outlook, 2024 (USD Billion)
- Fig. 16 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market Dynamics
- Fig. 17 Porter's five forces analysis
- Fig. 18 PESTEL analysis
- Fig. 19 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Type outlook and key takeaways
- Fig. 20 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Type movement analysis
- Fig. 21 Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Fig. 22 Branded Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Fig. 23 Generic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Fig. 24 Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Fig. 25 Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Fig. 26 Biosimilar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Fig. 27 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Product outlook and key takeaways
- Fig. 28 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Product movement analysis
- Fig. 29 Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Fig. 30 API Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 31 Traditional API Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 32 HP-API Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 33 Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 34 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 35 Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 36 Oral Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 37 Semi-Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 38 Liquid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 39 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 40 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Service outlook and key takeaways

Fig. 41 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Service movement analysis

Fig. 42 Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 43 Pre-formulation & Formulation Development Service Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 44 Process Development & Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 45 Analytical Testing & Method Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 46 Scale-up & Tech Transfer Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 47 Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 48 API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 49 Finished Drug Products Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 50 Packaging and Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 51 Regulatory Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 52 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 53 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Workflow outlook and key takeaways

Fig. 54 U.S. Pharmaceutical Contract Development and Manufacturing Organization Market: Workflow movement analysis

Fig. 55 Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 56 Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 57 U.S. Pharmaceutical Contract Development and Manufacturing Organization

Market: Therapeutic Area outlook and key takeaways

Fig. 58 U.S. Pharmaceutical Contract Development and Manufacturing Organization

Market: Therapeutic Area movement analysis

Fig. 59 Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 60 Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 61 Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 62 Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 63 Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 64 Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 65 Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 66 Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 67 Gastrointestinal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 68 Orthopedic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 69 Dental Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 70 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 71 U.S. Pharmaceutical Contract Development and Manufacturing Organization

Market: End Use outlook and key takeaways

Fig. 72 U.S. Pharmaceutical Contract Development and Manufacturing Organization

Market: End Use movement analysis

Fig. 73 Small Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 74 Medium Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 75 Large Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Fig. 76 Key company categorization

Fig. 77 Service heat map analysis

Fig. 78 Strategic framework

## I would like to order

Product name: U.S. Pharmaceutical Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Type, By Product, By Services, By Workflow, By Therapeutic Area, By End Use, And Segment Forecasts, 2025 - 2033

Product link: <https://marketpublishers.com/r/U366C97C2C9FEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U366C97C2C9FEN.html>